# Intellia Therapeutics Revenue Misses Estimates as GAAP Loss Per Share Hits $0.91

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/50304
Published: 2026-11-06T19:35:20.000Z
Updated: 2026-11-06T19:35:20.000Z
Section: Business

> Total revenue was $7.16 million, $2.61 million below estimates. Collaboration revenue fell 48% year over year to $7.2 million.

Intellia Therapeutics, Inc. posted a $0.91 GAAP loss per share for the third quarter of 2026, 11 cents worse than analyst estimates, while revenue also missed forecasts.

Total revenue came to $7.16 million, $2.61 million below estimates. Separately, collaboration revenue was $7.2 million, down 48% from $13.8 million in the third quarter of 2025.